Navigation Links
Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
Date:2/19/2013

itioned for sustainable long-term growth," said Paul Bisaro, President and CEO. 

"On a proforma basis for the full-year 2012, we launched more than 1,000 generic products globally, and filed more than 1,500 applications globally.  Our Actavis Pharma pipeline is among the strongest in the industry with over 185 ANDAs on file with the U.S. FDA, including 49 first-to-file opportunities, of which, 33 represent potential exclusive first-to-files."

"In our Actavis Specialty Brands business, we experienced growth from U.S. sales of our key promoted products including Rapaflo®, Crinone®, and Generess® Fe.
We expanded our brand portfolio globally as we launched Rapaflo®, Gelnique®, Androderm® and Oxytrol® in Canada and prepared for launches of key branded products in Latin America.  We continued to record progress in our biosimilar initiatives as we acquired a biosimilar to Herceptin® from Synthon and contributed the product to the Amgen collaboration which includes Herceptin®, Avastin®, Rituxan/MabThera® and Erbitux®. Additionally, rFSH entered into the Phase I clinical program."

In January 2013, we acquired Uteron Pharma SA which adds three near term and three longer term projects to our Women's Health development portfolio," Bisaro continued.

"In 2012, we continued to utilize our strong balance sheet as we issued $3.9 billion in senior unsecured notes and completed a new $1.8 billion term loan facility at favorable rates.  We are focused on repaying our debt and maintaining a strong financial foundation to support strategic growth initiatives within our global businesses," concluded Bisaro. 

Fourth Quarter and Full Year 2012 Business Segment ResultsActavis Pharma Segment InformationThree Months EndedTwelve Months Ende
'/>"/>

SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Watson to Acquire Actavis Group for EUR4.25 Billion
2. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
3. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
4. Watson and Actavis Receive FTC Second Request
5. Watson Announces New Name -- Actavis -- for Global Operations
6. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
7. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
8. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
9. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
10. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
11. Aethlon Medical Note: Fiscal Year Revenue Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... WASHINGTON , May 22, 2015  The ... certain diagnosed victims of mesothelioma get the best ... making certain individuals with this rare cancer caused ... the most up-to-date information related to treatment options ... information please call the Mesothelioma Victims Center anytime ...
(Date:5/22/2015)... --  InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the ... announced that its CGuard TM Embolic Prevention System reported ... Piotr Musialek , at the EuroPCR conference on ... PARADIGM, an investigator-initiated P rospective evaluation of ... revascularization I n symptomatic and increased-risk asymptomatic carotid ...
(Date:5/22/2015)... , May 22, 2015  In a sweeping ... the U.S., T1D Exchange researchers conclude that ... type 1 diabetes across all age groups, but especially ... most up-to-date picture of diabetes treatment, underscoring the need ... and technologies that can help type 1 patients achieve ...
Breaking Medicine Technology:Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5
... In a platform presentation at the 46th annual meeting ... (EASD) in Stockholm, investigators for Biodel Inc. (Nasdaq: ... clinical study evaluating a new pH-neutral formulation of Linjeta™ ... Research, Neuss, Germany) and colleagues reported that the new ...
... (Nasdaq: MYL ) today announced that its ... the U.S. Food and Drug Administration (FDA) for its ... mg, 1 mg and 5 mg, the generic version ... in people who have received certain organ transplants. ...
Cached Medicine Technology:Results of Linjeta™ Study Versus Insulin Lispro Reported Today in Platform Presentation at EASD Annual Meeting 2Results of Linjeta™ Study Versus Insulin Lispro Reported Today in Platform Presentation at EASD Annual Meeting 3
(Date:5/22/2015)... New York, NY (PRWEB) May 22, 2015 ... abstract entitled “Positivity Rates and Genotype Results in ‘Baby ... Action: Results from a Nationwide Lab Test Database” at Digestive ... conducted by Medivo’s Clinical Affairs and Analytics team members Carol ... Dhaliwal, MD; and Andrea Parker, MSI, along with Nancy Reau, ...
(Date:5/22/2015)... DMG Productions announces the upcoming airing of Innovations ... May 29, 2015 at 7:30 a.m. ET and 7:30 ... Innovations will explore Interstate Restoration, a company dedicated to ... recovery and restoration. , Additionally, the series will focus ... and deliver training and education in the areas of ...
(Date:5/22/2015)... 2015 In April 2006, Veatch Consulting ... 9 years they have concentrated their focus to working ... Canada. Because of this growth and their goals to ... in Denver, Colorado, Cleveland, Ohio, Houston, Texas and now ... new dental offices, dental start ups, orthodontic practices, pediatric ...
(Date:5/22/2015)... May 22, 2015 Puritan Medical ... for the medical, diagnostic, environmental, and forensics industries ... of products in the US. At a time ... outside the US, Puritan remains committed to designing ... their Guilford, Maine facility. , Since 1919, Puritan ...
(Date:5/22/2015)... Viejo, CA (PRWEB) May 22, 2015 ... editable lower thirds designed exclusively for Final Cut Pro ... compatible with any design. , Intuitive on-screen-controls allow ... unique lower third. Reflections, colors, layouts, and much more ... Inspector window. , Pro3rd Impression comes ...
Breaking Medicine News(10 mins):Health News:Medivo Study Finds HCV Positivity Rates are 250% Higher Among Baby Boomers 2Health News:New Episode of Innovations Airing Friday, May 29, 2015 Via Discovery Channel 2Health News:Maine Swab Company Celebrates 96 Years of American-made Products 2Health News:Developers at Pixel Film Studios Release Pro3rd Impression for Final Cut Pro X. 2
... , CUPERTINO, Calif., July 27 ... quarter 2009 financial results press release, you are invited to listen ... internet on Monday, August 3, 2009 at 4:30 pm Eastern Time ... http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) , , A live audio webcast ...
... of serious complications drop with intensive therapy, study shows ... controlling blood sugar levels and taking medications that lower ... can significantly reduce their risk of developing the most ... , In a study appearing in the July 27 ...
... 27 Danaher Corporation (NYSE: DHR ) announced today that ... effective as of the end of 2009. , , ... joining Danaher in 2000. , , "Phil ... portfolio over the past nine years," said H. Lawrence Culp, Jr., President ...
... , , ATLANTA, July 27 ... diagnosis and treatment of infertility with ovulation induction and insemination, surgery ... financial aspects. Discussions include information about age related infertility, fallopian tube ... donor eggs. , , You will also ...
... , , , ... Program officials announced today that Tennessee residents have saved over ... launch of the free statewide prescription assistance program. Tennessee Drug ... in May 2007. The program has no restrictions to membership, no ...
... , , MINNEAPOLIS, July 27 ... the world,s population, often resulting in patches of dry skin, and little ... in the teenage years but may continue throughout adulthood. There is ... Alan B. Fleischer, professor and chair of the department of dermatology at ...
Cached Medicine News:Health News:DURECT Corporation Invites You to Join Its Second Quarter 2009 Earnings Conference Call 2Health News:Tight Management of Type 1 Diabetes Worth the Effort 2Health News:Tight Management of Type 1 Diabetes Worth the Effort 3Health News:Tennessee Drug Card Has Saved Residents Over $7.3 Million 2Health News:What Is Keratosis Pilaris (KP)? 2
... SurgiGraphic 1027, with a Carbon Fiber ... designed for superior C-arm access, safety ... design means C-Arm utilization is quick ... exposure is minimized resulting in a ...
... The SurgiGraphic 6000 ... the tabletop for precise ... Float allows for immediate ... moving the C-Arm, making ...
... IMPLANT SYSTEM is a unique three-piece implant ... 1st metatarsal phalangeal joint resulting from osteoarthritis, ... a previous arthroplasty. The implant is ... superior function and longevity. With a ...
... play an important part in our daily ... rheumatic changes can cause severe handicaps. A ... finger-joint prostheses was to produce a reconstructed ... function as nearly possible.,The cementless RM Finger ...
Medicine Products: